BACKGROUND: Children with asthma exposed to secondhand smoke (SHS) might be at higher risk for severe exacerbations, but biomarkers of susceptibility to SHS exposure have not been previously reported. OBJECTIVES: We sought to assess the usefulness of urinary leukotriene E(4) (uLTE₄) levels in the prediction of increased risk of severe asthma exacerbations requiring emergency department (ED) or urgent care (UC) visits. METHODS: Forty-four schoolchildren with moderate-to-severe asthma receiving inhaled corticosteroids were followed for 5 months with repeated measurements of uLTE₄ and monitoring of ED and UC visits. SHS exposure status was determined by using prestudy questionnaires and repeated measurements of urinary cotinine during the study. RESULTS: Nine (45%) of 20 children with SHS exposure experienced a severe exacerbation requiring an ED or UC visit compared with 3 (12.5%) of 24 children without significant SHS exposure (relative risk, 3.6; 95% CI, 1.1-11.5; P = .02). The uLTE₄ level was a significant predictor of exacerbation risk in children exposed to SHS (area under the curve, 0.85; P = .003). Other predictors, such as nighttime symptom frequency, prebronchodilator and postbronchodilator lung function, and exhaled nitric oxide levels, were not related to exacerbations in this group. uLTE₄ levels at or greater than 106 pg/mg achieved 67% (6/9) sensitivity and 100% (11/11) specificity for predicting children with SHS exposure who required an ED or UC visit. CONCLUSIONS: Children exposed to SHS are at increased risk for severe asthma exacerbations, despite use of inhaled corticosteroids. uLTE₄ levels identify children exposed to SHS at high risk for asthma exacerbations.
BACKGROUND:Children with asthma exposed to secondhand smoke (SHS) might be at higher risk for severe exacerbations, but biomarkers of susceptibility to SHS exposure have not been previously reported. OBJECTIVES: We sought to assess the usefulness of urinary leukotriene E(4) (uLTE₄) levels in the prediction of increased risk of severe asthma exacerbations requiring emergency department (ED) or urgent care (UC) visits. METHODS: Forty-four schoolchildren with moderate-to-severe asthma receiving inhaled corticosteroids were followed for 5 months with repeated measurements of uLTE₄ and monitoring of ED and UC visits. SHS exposure status was determined by using prestudy questionnaires and repeated measurements of urinary cotinine during the study. RESULTS: Nine (45%) of 20 children with SHS exposure experienced a severe exacerbation requiring an ED or UC visit compared with 3 (12.5%) of 24 children without significant SHS exposure (relative risk, 3.6; 95% CI, 1.1-11.5; P = .02). The uLTE₄ level was a significant predictor of exacerbation risk in children exposed to SHS (area under the curve, 0.85; P = .003). Other predictors, such as nighttime symptom frequency, prebronchodilator and postbronchodilator lung function, and exhaled nitric oxide levels, were not related to exacerbations in this group. uLTE₄ levels at or greater than 106 pg/mg achieved 67% (6/9) sensitivity and 100% (11/11) specificity for predicting children with SHS exposure who required an ED or UC visit. CONCLUSIONS:Children exposed to SHS are at increased risk for severe asthma exacerbations, despite use of inhaled corticosteroids. uLTE₄ levels identify children exposed to SHS at high risk for asthma exacerbations.
Authors: Stephen C Lazarus; Vernon M Chinchilli; Nancy J Rollings; Homer A Boushey; Reuben Cherniack; Timothy J Craig; Aaron Deykin; Emily DiMango; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Robert F Lemanske; Frank T Leone; Richard J Martin; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Stanley J Szefler; Michael E Wechsler; John V Fahy Journal: Am J Respir Crit Care Med Date: 2007-01-04 Impact factor: 21.405
Authors: Joshua E Muscat; Mirjana V Djordjevic; Stephen Colosimo; Steven D Stellman; John P Richie Journal: Cancer Date: 2005-04-01 Impact factor: 6.860
Authors: Frederik Buchvald; Eugenio Baraldi; Silvia Carraro; Benjamin Gaston; Johan De Jongste; Mariëlle W H Pijnenburg; Philip E Silkoff; Hans Bisgaard Journal: J Allergy Clin Immunol Date: 2005-06 Impact factor: 10.793
Authors: Jason E Lang; Allen J Dozor; Janet T Holbrook; Edward Mougey; Sankaran Krishnan; Shawn Sweeten; Robert A Wise; W Gerald Teague; Christine Y Wei; David Shade; John J Lima Journal: J Allergy Clin Immunol Pract Date: 2013-01-12
Authors: Randi K Johnson; Tonya Brunetti; Kevin Quinn; Katrina Doenges; Monica Campbell; Christopher Arehart; Margaret A Taub; Rasika A Mathias; Nichole Reisdorph; Kathleen C Barnes; Michelle Daya Journal: J Allergy Clin Immunol Date: 2021-11-12 Impact factor: 14.290